BIROn - Birkbeck Institutional Research Online

    Mycobactin analogues with excellent pharmacokinetic profile demonstrate potent antitubercular specific activity and exceptional efflux pump inhibition

    Shyam, M. and Verma, H. and Bhattacharje, G. and Mukherjee, P. and Singh, S. and Kamilya, S. and Jalani, P. and Das, S. and Dasgupta, A. and Mondal, A. and Das, A.K. and Singh, A. and Brucoli, F. and Bagneris, Claire and Dickman, R. and Basavanakatti, V.N. and Naresh Babu, P. and Sankaran, V. and Dev, A. and Sinha, B.N. and Bhakta, Sanjib and Jayaprakash, V. (2022) Mycobactin analogues with excellent pharmacokinetic profile demonstrate potent antitubercular specific activity and exceptional efflux pump inhibition. Journal of Medicinal Chemistry 65 (1), pp. 234-256. ISSN 0022-2623.

    [img] Text
    Final_Manuscript_20.12.21.docx - Author's Accepted Manuscript
    Restricted to Repository staff only until 4 January 2023.

    Download (3MB) | Request a copy

    Abstract

    In this study, we have designed and synthesized pyrazoline analogues that partially mimic the structure of mycobactin, to address the requirement of novel therapeutics to tackle the emerging global challenge of antimicrobial resistance (AMR). Our investigation resulted in the identification of novel lead compounds 44 and 49 as potential mycobactin biosynthesis inhibitors against mycobacteria. Moreover, candidates efficiently eradicated intracellularly surviving mycobacteria. Thermofluorimetric analysis and molecular dynamics simulations suggested that compounds 44 and 49 bind to salicyl-AMP ligase (MbtA), a key enzyme in the mycobactin biosynthetic pathway. To the best of our knowledge, these are the first rationally designed mycobactin inhibitors to demonstrate an excellent in vivo pharmacokinetic profile. In addition, these compounds also exhibited more potent whole-cell efflux pump inhibition than known efflux pump inhibitors verapamil and chlorpromazine. Results from this study pave the way for the development of 3-(2-hydroxyphenyl)-5-(aryl)-pyrazolines as a new weapon against superbug-associated AMR challenges.

    Metadata

    Item Type: Article
    Additional Information: © ACM, 2022. This is the author's version of the work. It is posted here by permission of ACM for your personal use. Not for redistribution. The definitive version was published at the link above.
    School: School of Science > Biological Sciences
    Depositing User: Sanjib Bhakta
    Date Deposited: 14 Mar 2022 13:51
    Last Modified: 14 Mar 2022 13:51
    URI: https://eprints.bbk.ac.uk/id/eprint/47225

    Statistics

    Activity Overview
    6 month trend
    1Download
    6 month trend
    40Hits

    Additional statistics are available via IRStats2.

    Archive Staff Only (login required)

    Edit/View Item Edit/View Item